Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) General Counsel David O. Watson sold 4,240 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $66.81, for a total transaction of $283,274.40. Following the transaction, the general counsel now owns 109,261 shares in the company, […]
Assetmark Inc. grew its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 88.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,369 shares of the company’s stock after purchasing an additional 5,339 shares during […]
Jacob Asset Management of New York LLC raised its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 1,017.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,850 shares of the company’s stock after buying an additional 4,416 shares during the quarter. […]
Inspire Advisors LLC reduced its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 50.9% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,115 shares of the company’s stock after selling 6,342 shares during the period. Inspire […]
Orion Portfolio Solutions LLC lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 64.2% in the 3rd quarter, Holdings Channel.com reports. The fund owned 27,396 shares of the company’s stock after buying an additional 10,713 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Apellis Pharmaceuticals were worth $1,042,000 at the […]